Researchers have developed a blood test that can estimate the age at which Alzheimer’s disease symptoms will appear, according to a study published in Nature Medicine on February 19, 2026.
The study, authored by Kellen K. Petersen, Marta Milà-Alomà, Yan Li, and 29 other authors, used “clock” models based on longitudinal plasma %p-tau217 levels—the ratio of phosphorylated to non-phosphorylated tau at position 217—to predict the onset of symptoms in cognitively unimpaired individuals.
Using data from two independent cohorts (n = 258 and n = 345), the researchers found that the estimated age of p-tau217 positivity was associated with the actual age of symptom onset, with an adjusted R2 of 0.337–0.612 and a median absolute error ranging between 3.0 and 3.7 years, the report noted.
“In the near term, these models will accelerate our research and clinical trials,” Suzanne Schindler of Washington University in St. Louis said.
Predicting symptom onset timing
The time from %p-tau217 positivity to the onset of Alzheimer’s disease symptoms was shorter in older individuals, researchers found.

The study was supported by funding from the NIH’s National Institute on Aging (NIA), the Foundation for the National Institutes of Health, AbbVie, the Alzheimer’s Association, the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation, Biogen, Janssen Research & Development, and Takeda Pharmaceutical Company.
Measuring advanced tau pathology
Current blood tests often focus on proteins like beta-amyloid and phosphorylated tau, which rise early in the disease process but provide limited data on the buildup of tau tangles in later stages. Research published in 2025 and 2026 linked higher concentrations of this biomarker to tau accumulation and faster cognitive decline, but previously, measuring it required specialized mass spectrometry available in relatively few laboratories.
To test the immunoassay, researchers utilized blood samples from 521 brain donors collected prior to death from two US autopsy cohorts, as well as 207 participants drawn from two tau PET imaging cohorts.
Within one of the imaging cohorts, participants exhibiting advanced tau pathology showed concentrations nearly 60 times higher than those who showed no detectable tau abnormalities on PET imaging. The researchers said that many measurements in the comparison groups were below the assay’s quantification limit, though differences remained substantial in more conservative analyses.
According to the study, which appeared online in JAMA on November 16, both the immunoassay and mass spectrometry demonstrated similarly high accuracy in identifying regional tau-PET positivity, with AUCs between 0.96 and 0.99 for the immunoassay and between 0.97 and 0.99 for mass spectrometry.
Having a simple yet highly scalable way to determine the extent of tau tangle buildup in the brain represents a major step forward in our understanding of Alzheimer’s. Nicholas Ashton, PhD, senior director of Banner’s Fluid Biomarker Program at Banner Sun Health Research Institute, said
Ashton said that the smaller blood volume required for this test could support remote blood collection and decentralized research, though these applications require further study. The study was supported by multiple research grants and foundations, with Bioventix supplying antibodies and Alamar Biosciences performing the immunoassay measurements. Ashton reported having advisory, educational, and consulting relationships with multiple companies, including Alamar Biosciences.
Blood tests may cause anxiety in asymptomatic people
Medical experts caution that these emerging blood tests are not currently intended for standalone diagnosis or for use in people without symptoms. Dr. David Holtzman, a neurologist mentioned in relation to blood tests for amyloid in the brain,.

For individuals who are cognitively normal, a positive test result could potentially cause unnecessary distress, Holtzman told NPR. He said that for people without memory loss or other symptoms, a positive result can be a source of needless anxiety.
Right now, if you did get a test like that and you're still cognitively normal, there's nothing that we know medically to do about that. Holtzman said
However, Michael Malek-Ahmadi, a scientist at Banner Health in Phoenix, said that even people without symptoms may learn something, as those at or above a certain threshold are known to be at a higher risk of progressing to Alzheimer’s symptoms.
This research comes from Washington University in St. Louis, a private institution founded in 1853 to address the lack of higher learning in the Midwest. Originally known as Eliot Seminary, the university began holding classes in 1854 in a loaned schoolhouse. It has since grown into a major research hub with an endowment of $12.0 billion, which ranks among the fifteen largest in the United States.
Tatiana Marcal, MD, senior director of medical affairs and clinical programs at the Alzheimer’s Association, suggested that these tools might eventually complement rather than replace existing biomarkers.
Speaking to Medscape Medical News, Marcal said, “P-tau217 and eMTBR-tau are likely complementary, and there may eventually be a series or panel that could measure and help with staging of someone’s underlying biology.” She added that while p-tau217 helps identify Alzheimer’s pathology, eMTBR-tau may provide additional information regarding disease stage and tau burden.
Eventually, the goal is to be able to estimate when individuals are likely to develop symptoms, which will help them and their doctors to develop a plan to prevent or slow symptoms. Schindler said
Earlier coverage: Researchers Develop Blood Test to Track Alzheimer's Progression